Live news: Biogen halves price of Alzheimer’s drug after sales fall short of expectations
Biogen has halved the price of its Alzheimer’s drug Aduhelm, after sales fell short of expectations because insurers have been reluctant to pay for the treatment. The Boston-based biotech said it would now charge a list price of $28,200…